Business Description
Mesoblast Ltd
ISIN : US5907174016
Share Class Description:
MESO: ADRTotal Employee Number:
81Description
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.96 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.6 | |||||
3-Year EBITDA Growth Rate | 13 | |||||
3-Year EPS without NRI Growth Rate | 18.2 | |||||
3-Year FCF Growth Rate | 22.6 | |||||
3-Year Book Growth Rate | -11.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 128.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.78 | |||||
9-Day RSI | 65.9 | |||||
14-Day RSI | 59.75 | |||||
3-1 Month Momentum % | -8 | |||||
6-1 Month Momentum % | -34.16 | |||||
12-1 Month Momentum % | 25.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.58 | |||||
Quick Ratio | 1.41 | |||||
Cash Ratio | 1.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.1 | |||||
Shareholder Yield % | -0.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -304.71 | |||||
OCF Margin % | -296.96 | |||||
3-Year ROIIC % | 14.06 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
Forward PE Ratio | 257.33 | |||||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PS Ratio | 101.82 | |||||
PB Ratio | 3.34 | |||||
Price-to-Tangible-Book | 320 | |||||
EV-to-EBIT | -23.62 | |||||
EV-to-Forward-EBIT | -41.11 | |||||
EV-to-EBITDA | -23.62 | |||||
EV-to-Forward-EBITDA | -53.8 | |||||
EV-to-Revenue | 109.93 | |||||
EV-to-Forward-Revenue | 10.99 | |||||
EV-to-FCF | -36.66 | |||||
Price-to-GF-Value | 8.26 | |||||
Earnings Yield (Greenblatt) % | -4.23 | |||||
FCF Yield % | -2.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MESO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17.198 | ||
| EPS (TTM) ($) | - | ||
| Beta | 1.3103 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.35 | ||
| Volatility % | 48.78 | ||
| 14-Day RSI | 59.75 | ||
| 14-Day ATR ($) | 0.637768 | ||
| 20-Day SMA ($) | 14.36675 | ||
| 12-1 Month Momentum % | 25.23 | ||
| 52-Week Range ($) | 10.805 - 21.5 | ||
| Shares Outstanding (Mil) | 129.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-25 10:30 | In 138 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-28 08:30 | In 49 days | ||
| Annual report for 2026 | 2026-08-28 | In 48 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 48 days | ||
| inaugural R&D Day | 2026-04-08 08:00 | 13.69 (-1.40%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-26 17:00 | 16.91 (+1.02%) | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 16.91 (+1.02%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-04 12:00 | 16.93 (+2.67%) | ||
| General meeting for 2025 | 2025-11-25 10:30 | 15.62 (+2.02%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-29 08:30 | 15.95 (-0.68%) |
Show
Entries
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(MESO)'s stock price today?
The current price of MESO is $15.46. The 52 week high of MESO is $21.50 and 52 week low is $10.81.
When is next earnings date of Mesoblast Ltd(MESO)?
The next earnings date of Mesoblast Ltd(MESO) is 2026-08-28 Est..
Does Mesoblast Ltd(MESO) pay dividends? If so, how much?
Mesoblast Ltd(MESO) does not pay dividend.
Guru Commentaries on NAS:MESO
No articles.
Press Release
Articles on Mesoblast Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers